x
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
o
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
|
NEURO-HITECH,
INC.
|
|
|
(Exact
name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
20-4121393
|
(State
or Other Jurisdiction of
|
|
(I.R.S.
Employer
|
Incorporation
or Organization)
|
|
Identification
No.)
|
|
|
|
|
450
7th
Avenue, Suite 1106, New York, NY 10123
|
|
|
(Address
of Principal Executive Offices)
|
|
|
|
|
|
(212)
798-8121
|
|
|
(Issuer’s
Telephone Number, Including Area Code)
|
|
|
|
|
|
One
Penn Plaza, Suite 1503, New York, NY 10019
|
|
|
(Former
Name, Former Address and Former Fiscal Year
If
Changed Since Last Report)
|
|
Large Accelerated Filer
o
|
Accelerated Filer
o
|
Non-Accelerated Filer
o
|
Smaller Reporting Company
x
|
|
(Do Not Check if a smaller reporting company)
|
|
September
30,
|
December
31,
|
||||||
ASSETS
|
2008
|
2007
|
|||||
(Unaudited)
|
(1)
|
||||||
Current
Assets:
|
|||||||
Cash
and cash equivalents
|
$
|
159,858
|
$
|
6,137,592
|
|||
Accounts
receivable
|
129,600
|
63,300
|
|||||
Inventory
|
202,724
|
33,821
|
|||||
Prepaid
expenses
|
302,444
|
11,861
|
|||||
Total
current assets
|
794,626
|
6,246,574
|
|||||
Fixed
assets, net of accumulated depreciation of $6,241 and $4,747 at
September
30, 2008 and
|
|||||||
December
31, 2007, respectively
|
7,626
|
4,248
|
|||||
Intangible
assets, net of accumulated amortization of $432,516 and $0 at September
30, 2008 and
|
|||||||
December
31, 2007, respectively - (see note 3)
|
12,542,960
|
-
|
|||||
Security
deposit
|
-
|
13,226
|
|||||
Total
assets
|
$
|
13,345,212
|
$
|
6,264,048
|
|||
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
|||||||
Current
Liabilities:
|
|||||||
Accounts
payable and accrued expenses
|
$
|
1,669,541
|
$
|
1,000,399
|
|||
Convertible
note payable, including accrued interest of $48,082 and $0 at September
30, 2008 and
|
|||||||
December
31, 2007, respectively - (see note 3)
|
3,048,082
|
-
|
|||||
Subordinated
note payable, including accrued interest of $67,316 and $0 at September
30, 2008 and
|
|||||||
December
31, 2007, respectively - (see note 3)
|
3,067,316
|
-
|
|||||
Accrued
sales allowance
|
1,636,138
|
-
|
|||||
Total
current liabilities
|
9,421,077
|
1,000,399
|
|||||
Stockholders'
Equity:
|
|||||||
Preferred
stock, $.001 par value, 5,000,000 shares authorized:
|
|||||||
Series
A, none issued and outstanding at September 30, 2008 and December
31,
2007
|
-
|
-
|
|||||
Series
B, none issued and outstanding at September 30, 2008 and December
31,
2007
|
-
|
-
|
|||||
Common
stock - Class A, $.001 par value, 100 shares authorized, none issued
and
outstanding at
|
|||||||
September
30, 2008 and December 31, 2007
|
-
|
-
|
|||||
Common
stock, $.001 par value, 44,999,990 shares authorized, 31,520,303
and
14,004,853 issued
|
|||||||
and
outstanding at September 30, 2008 and December 31, 2007,
respectively
|
31,520
|
14,005
|
|||||
Subscriptions
receivable
|
(15,000
|
)
|
-
|
||||
Additional
paid-in capital
|
46,952,929
|
38,080,297
|
|||||
Accumulated
deficit
|
(43,045,314
|
)
|
(32,830,653
|
)
|
|||
Total
stockholders' equity
|
3,924,135
|
5,263,649
|
|||||
Total
liabilities and stockholders' equity
|
$
|
13,345,212
|
$
|
6,264,048
|
(1) |
Derived
from audited financial statements
|
For
the three-month period ended
|
For
the nine-month period ended
|
||||||||||||
September
30,
|
September
30,
|
||||||||||||
2008
|
2007
|
2008
|
2007
|
||||||||||
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
||||||||||
|
|||||||||||||
Revenues
|
$
|
46,238
|
$
|
112,455
|
$
|
433,377
|
$
|
363,740
|
|||||
Cost
of goods sold
|
793,167
|
56,203
|
984,563
|
167,262
|
|||||||||
Gross
Profit
|
(746,929
|
)
|
56,252
|
(551,186
|
)
|
196,478
|
|||||||
Operating
expenses:
|
|||||||||||||
Selling,
general and administrative expenses
|
2,418,347
|
2,297,636
|
8,059,997
|
4,655,230
|
|||||||||
Research
and development costs
|
-
|
760,158
|
1,553,408
|
2,482,821
|
|||||||||
Total
operating expenses
|
2,418,347
|
3,057,794
|
9,613,405
|
7,138,051
|
|||||||||
Operating
loss
|
(3,165,276
|
)
|
(3,001,542
|
)
|
(10,164,591
|
)
|
(6,941,573
|
)
|
|||||
Other
income:
|
|||||||||||||
Interest
income (expense)
|
(13,001
|
)
|
46,586
|
(50,070
|
)
|
166,874
|
|||||||
Net
loss
|
$
|
(3,178,277
|
)
|
$
|
(2,954,956
|
)
|
$
|
(10,214,661
|
)
|
$
|
(6,774,699
|
)
|
|
Basic
and diluted loss per common share
|
$
|
(0.10
|
)
|
$
|
(0.24
|
)
|
$
|
(0.48
|
)
|
$
|
(0.55
|
)
|
|
Basic
and diluted weighted average common
|
|||||||||||||
shares
outstanding
|
31,520,303
|
12,356,931
|
21,336,436
|
12,272,348
|
For
the nine-month period ended
|
|||||||
September
30,
|
|||||||
2008
|
2007
|
||||||
(Unaudited)
|
(Unaudited)
|
||||||
Cash
flows from operating activities:
|
|||||||
Net
loss
|
$
|
(10,214,661
|
)
|
$
|
(6,774,699
|
)
|
|
Adjustments
to reconcile net loss to net cash used in
|
|||||||
operating activities:
|
|||||||
Depreciation
|
1,494
|
2,249
|
|||||
Amortization
of intangible assets
|
432,516
|
-
|
|||||
Fair
value of options, warrants, and stock appreciation rights
|
3,808,081
|
2,927,497
|
|||||
Fair
value of shares issued for services
|
422,450
|
-
|
|||||
Changes
in operating assets and liabilities:
|
|||||||
Accounts
receivable
|
(66,300
|
)
|
(61,755
|
)
|
|||
Inventory
|
43,969
|
(42,895
|
)
|
||||
Prepaid
expenses
|
(290,583
|
)
|
(690
|
)
|
|||
Deferred
charges
|
-
|
93,750
|
|||||
Other
assets
|
13,226
|
(13,226
|
)
|
||||
Accounts
payable and accrued expenses
|
569,140
|
80,630
|
|||||
Accrued
sales allowance
|
218,039
|
-
|
|||||
Accrued
interest on convertible note payable
|
48,082
|
-
|
|||||
Accrued
interest on subordinated note payable
|
67,316
|
-
|
|||||
Net
cash used in operating activities
|
(4,947,231
|
)
|
(3,789,139
|
)
|
|||
Cash
flows used in investing activities:
|
|||||||
Purchase
of property and equipment
|
(4,872
|
)
|
-
|
||||
Acquisition
of intangible assets, net of cash acquired
|
(4,303,581
|
)
|
-
|
||||
Net
cash used in investing activities
|
(4,308,453
|
)
|
-
|
||||
Cash
flows from financing activities:
|
|||||||
Proceeds
from exercise of options
|
-
|
45,824
|
|||||
Issuance
of common stock pursuant to private placement
|
3,277,950
|
2,220,805
|
|||||
Net
cash provided by financing activities
|
3,277,950
|
2,266,629
|
|||||
Net
decrease in cash
|
(5,977,734
|
)
|
(1,522,510
|
)
|
|||
Cash
and cash equivalent, beginning of period
|
6,137,592
|
4,705,195
|
|||||
Cash
and cash equivalent, end of period
|
$
|
159,858
|
$
|
3,182,685
|
|||
Supplemental
disclosures of cash flow information:
|
|||||||
Cash
paid for taxes
|
$
|
-
|
$
|
-
|
|||
Cash
paid for interest
|
$
|
-
|
$
|
-
|
|||
Noncash
investing and financing activities:
|
|||||||
Fair
value of Common Stock issued in connection with the acquisition
of
intangible assets
|
$
|
1,366,666
|
-
|
September
30, 2008
|
September
30, 2007
|
||||||
Options
|
6,238,078
|
1,311,242
|
|||||
Warrants
|
3,936,945
|
1,941,491
|
|||||
Convertible
note
|
1,500,000
|
-
|
|||||
11,675,023
|
3,252,733
|
Cash
|
$
|
4,492,624
|
||
Notes
|
6,000,000
|
|||
Fair
value of shares
|
1,366,666
|
|||
Assumption
of liabilities
|
1,518,161
|
|||
$
|
13,377,451
|
Cash
|
$
|
189,042
|
||
Inventory
|
212,872
|
|||
Intangible
assets
|
12,975,537
|
|||
$
|
13,377,451
|
ASSETS
|
September
30, 2008
|
Proforma
Adjustments
|
Total
|
|||||||
|
(Unaudited)
|
|||||||||
Current
Assets:
|
||||||||||
Cash
and cash equivalents
|
$
|
159,858
|
$
|
-
|
$
|
159,858
|
||||
Accounts
receivable
|
129,600
|
-
|
129,600
|
|||||||
Inventory
|
202,724
|
-
|
202,724
|
|||||||
Prepaid
expenses
|
302,444
|
1,257,717
|
(a) |
1,560,161
|
||||||
Total
current assets
|
794,626
|
1,257,717
|
2,052,343
|
|||||||
Fixed
assets, net of accumulated depreciation of $6,241
|
||||||||||
at
September 30, 2008
|
7,626
|
-
|
7,626
|
|||||||
Intangible
assets, net of accumulated amortization of $432,517
|
||||||||||
at
September 30, 2008
|
12,542,960
|
(4,475,652
|
)
(a)
|
8,067,308
|
||||||
Total
assets
|
$
|
13,345,212
|
$
|
(3,217,935
|
)
|
$
|
10,127,277
|
|||
LIABILITIES
AND STOCKHOLDERS’ EQUITY
|
||||||||||
Current
Liabilities:
|
||||||||||
Accounts
payable and accrued expenses
|
$
|
1,669,541
|
$
|
-
|
$
|
1,669,541
|
||||
Convertible
note payable, including accrued interest of $48,082
|
||||||||||
at
September 30, 2008
|
3,048,082
|
(3,048,082
|
)
(a)
|
-
|
||||||
Subordinated
note payable, including accrued interest of $67,316
|
||||||||||
at
September 30, 2008
|
3,067,316
|
(3,067,316
|
)
(a)
|
-
|
||||||
Accrued
sales allowance
|
1,636,138
|
-
|
1,636,138
|
|||||||
Total
current liabilities
|
9,421,077
|
(6,115,398
|
)
|
3,305,679
|
||||||
Stockholders’
Equity:
|
||||||||||
Preferred
stock, $.001 par value, 5,000,000 shares authorized:
|
||||||||||
Series
A, 1,500,000 issued and outstanding at November 17, 2008
|
-
|
1,500,000
|
(a) |
1,500,000
|
||||||
Series
B, 1,397,463 issued and outstanding at November 17, 2008
|
-
|
1,397,463
|
(a) |
1,397,463
|
||||||
Common
stock - Class A, $.001 par value, 100 shares authorized
|
||||||||||
none
issued and outstanding at September 30, 2008
|
-
|
-
|
-
|
|||||||
Common
stock, $.001 par value, 44,999,990 shares authorized 31,520,303
issued and outstanding at September 30, 2008
|
31,520
|
-
|
31,520
|
|||||||
Subscriptions
receivable
|
(15,000
|
)
|
-
|
(15,000
|
)
|
|||||
Additional
paid-in capital
|
46,952,929
|
-
|
46,952,929
|
|||||||
Accumulated
deficit
|
(43,045,314
|
)
|
-
|
(43,045,314
|
)
|
|||||
Total
stockholders’ equity
|
3,924,135
|
2,897,463
|
6,821,598
|
|||||||
Total
liabilities and stockholders’ equity
|
$
|
13,345,212
|
$
|
(3,217,935
|
)
|
$
|
10,127,277
|
(a) |
To
reflect the issuance of 1,500,000 shares and 1,397,463 shares of
the
Company’s Series A and B Preferred Stock, respectively, to satisfy the
Company’s obligations under the Convertible and Subordinated Note Payable,
the receipt by the Company of a right to receive future products
from an
affiliate of Seller with a corresponding net decrease of the carrying
value of the intangible assets.
|
Nine
month period ended
|
Nine
month period ended
|
||||||
September
30, 2008
|
September
30, 2007
|
||||||
Exercise
price:
|
$
|
0.44
- $5.85
|
$
|
5.29
- 5.35
|
|||
Market
price at date of grant:
|
$
|
0.41
- $0.45
|
$
|
5.29
- 5.35
|
|||
Volatility:
|
121.63
|
%
|
53.43
|
%
|
|||
Expected
dividend rate:
|
0
|
%
|
0
|
%
|
|||
Expected
terms:
|
4
- 5 years
|
5
years
|
|||||
Risk-free
interest rate:
|
3.2
- 3.52
|
%
|
4.24
|
%
|
|||
Stock
options granted:
|
4,050,000
|
806,825
|
|||||
Stock
appreciation rights granted:
|
365,000
|
-
|
Year
|
Amount
|
|||
2009
|
$
|
465,000
|
||
2010
|
20,000
|
|||
2011
|
0
|
|||
2012
|
0
|
|||
Total
|
$
|
485,000
|
Nine-month
period ended
|
Nine-month
period ended
|
||||||||||||||||||||||||
September
30, 2008
|
September
30, 2007
|
||||||||||||||||||||||||
Neuro-Hitech
|
MCR/AMBI
|
Pro
Forma
Adjustment
|
Total
|
Neuro-Hitech
|
MCR/AMBI
|
Pro
Forma Adjustment
|
Total
|
||||||||||||||||||
Revenues
|
$
|
433,377
|
$
|
1,322,557
|
$
|
-
|
$
|
1,755,934
|
$
|
363,740
|
$
|
6,238,861
|
$
|
(608,381
|
)
|
$
|
5,994,220
|
||||||||
Cost
of goods sold
|
216,205
|
1,775,392
|
-
|
1,991,597
|
167,262
|
925,577
|
(53,680
|
)
|
1,039,159
|
||||||||||||||||
Gross
profit
|
217,172
|
(452,835
|
)
|
-
|
(235,663
|
)
|
196,478
|
5,313,284
|
(554,701
|
)
|
4,955,061
|
||||||||||||||
Operating
expenses:
|
|||||||||||||||||||||||||
Selling,
general, & administrative
|
7,031,755
|
3,323,805
|
540,645
|
(a) |
10,896,205
|
4,655,230
|
3,729,685
|
(227,087
|
)
(a)
|
8,157,828
|
|||||||||||||||
Product
development
|
-
|
31,235
|
-
|
31,235
|
-
|
364,522
|
-
|
364,522
|
|||||||||||||||||
Research
& development costs
|
1,553,408
|
-
|
-
|
1,553,408
|
2,482,821
|
-
|
-
|
2,482,821
|
|||||||||||||||||
Total
operating expenses
|
8,585,163
|
3,355,040
|
540,645
|
12,480,848
|
7,138,051
|
4,094,207
|
(227,087
|
)
|
11,005,171
|
||||||||||||||||
Operating
income (loss)
|
(8,367,991
|
)
|
(3,807,875
|
)
|
(540,645
|
)
|
(12,716,511
|
)
|
(6,941,573
|
)
|
1,219,077
|
(327,614
|
)
|
(6,050,110
|
)
|
||||||||||
Other
income :
|
|||||||||||||||||||||||||
Interest
income (expense)
|
50,410
|
-
|
(154,603
|
)
(b)
|
(104,193
|
)
|
166,874
|
68,312
|
(32,718
|
)
(b)
|
202,468
|
||||||||||||||
Net
income (loss)
|
$
|
(8,317,581
|
)
|
$
|
(3,807,875
|
)
|
$
|
(695,248
|
)
|
$
|
(12,820,704
|
)
|
$
|
(6,774,699
|
)
|
$
|
1,287,389
|
$
|
(360,332
|
)
|
$
|
(5,847,642
|
)
|
||
Basic
and diluted loss per
|
|||||||||||||||||||||||||
Common
share
|
$
|
(0.51
|
)
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
|||||||||||||||
Basic
and diluted weighted average common shares
|
|||||||||||||||||||||||||
outstanding
|
16,216,370
|
N/A
|
8,574,074
|
(c) |
24,790,444
|
12,272,348
|
N/A
|
N/A
|
(c) |
12,272,348
|
(a) |
Represents
the amortization of intangible assets acquired pursuant to the acquisition
of AMBI and MCR, based on its initial valuation of the various intangible
assets acquired as if the acquisition occurred at the beginning of
the
nine-month periods ended September 30, 2008 and 2007,
respectively.
|
(b) |
Consists
of the interest related to the convertible and subordinated note
payable
issued pursuant to the acquisition of MCR and AMBI as if the acquisition
occurred at the beginning of the nine-month periods ended September
30,
2008 and 2007, respectively.
|
(c) |
Consists
of 3,333,333 shares of common stock issued pursuant to the acquisition
of
MCR and AMBI and 12,100,000 shares issued pursuant to a private placement
to partially fund the purchase price of MCR and AMBI as if the acquisition
occurred at the beginning of the nine-month periods ended September
30,
2008 and 2007, respectively.
|
For
the three-month
period
ended
|
For
the nine-month
period
ended
|
||||||||||||||||||||||||
September
30
|
2008
vs 2007
|
2008
vs 2007
|
September
30
|
2008
vs 2007
|
2008
vs 2007
|
||||||||||||||||||||
2008
|
2007
|
($)
|
(%)
|
2008
|
2007
|
($)
|
(%)
|
||||||||||||||||||
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
||||||||||||||||||||||
|
|||||||||||||||||||||||||
Revenues
|
$
|
46,238
|
$
|
112,455
|
$
|
(66,217
|
)
|
-59
|
%
|
$
|
433,377
|
$
|
363,740
|
$
|
69,637
|
19
|
%
|
||||||||
Cost
of goods sold
|
793,167
|
56,203
|
736,964
|
NM
|
984,563
|
167,262
|
817,301
|
NM
|
|||||||||||||||||
Gross
Profit
|
(746,929
|
)
|
56,252
|
(803,181
|
)
|
-1428
|
%
|
(551,186
|
)
|
196,478
|
(747,664
|
)
|
-381
|
%
|
|||||||||||
|
|||||||||||||||||||||||||
Operating
expenses:
|
|||||||||||||||||||||||||
Selling,
general and administrative expenses
|
2,418,347
|
2,297,636
|
120,711
|
5
|
%
|
8,059,997
|
4,655,230
|
3,404,767
|
73
|
%
|
|||||||||||||||
Research
and development costs
|
-
|
760,158
|
(760,158
|
)
|
-100
|
%
|
1,553,408
|
2,482,821
|
(929,413
|
)
|
-37
|
%
|
|||||||||||||
Total
operating expenses
|
2,418,347
|
3,057,794
|
(639,447
|
)
|
-21
|
%
|
9,613,405
|
7,138,051
|
2,475,354
|
35
|
%
|
||||||||||||||
Operating
loss
|
(3,165,276
|
)
|
(3,001,542
|
)
|
163,734
|
5
|
%
|
(10,164,591
|
)
|
(6,941,573
|
)
|
3,223,018
|
46
|
%
|
|||||||||||
Other
income (expense):
|
|||||||||||||||||||||||||
Interest
income (expense)
|
(13,001
|
)
|
46,586
|
59,587
|
NM
|
(50,070
|
)
|
166,874
|
216,944
|
NM
|
|||||||||||||||
Net
loss
|
$
|
(3,178,277
|
)
|
$
|
(2,954,956
|
)
|
$
|
223,321
|
8
|
%
|
$
|
(10,214,661
|
)
|
$
|
(6,774,699
|
)
|
$
|
3,439,962
|
51
|
%
|
· |
Net
loss of approximately $10 million, adjusted for share-based payments
aggregating $4.5 million and the amortization of intangible assets
acquired pursuant to the MCR and AMBI acquisition amounting to
approximately $433,000;
|
· |
A
decrease in accounts receivable of approximately $66,300 which is
primarily due to quicker collection cycles experienced from one of
the
Company’s clients at September 30, 2008 then at December 31,
2007;
|
· |
A
decrease in deferred charges related to the Phase II results;
and
|
· |
An
increase in accounts payable and accrued expenses of approximately
$569,000 primarily due to payables assumed from the acquisition of
MCR and
AMBI
|
·
|
the
number of potential products in
development;
|
·
|
costs
of developing sales, marketing and distribution channels and the
Company’s
ability to sell its drugs;
|
·
|
competing
technological and market
developments;
|
·
|
market
acceptance or the Company’s products;
and
|
·
|
costs
for recruiting and retaining management, employees and
consultants.
|
· |
reformulation
of the product;
|
· |
additional
testing;
|
· |
clinical
trials; or
|
· |
changes
in the labeling or marketing of the
product.
|
· |
controls
on healthcare spending through limitations on the growth of private
health
insurance premiums and Medicare and Medicaid
spending;
|
· |
the
increased use of managed care contractors by government payors;
and
|
· |
price
controls on pharmaceutical
products.
|
•
|
|
Difficulties
in integrating the operations, technologies, products and personnel
of the
acquired companies;
|
||
|
||||
•
|
|
Diversion
of management’s attention from normal daily operations of the
business;
|
||
|
||||
•
|
|
Difficulties
in entering markets in which we have no or limited direct prior experience
and where competitors in such markets have stronger market
positions;
|
||
|
||||
•
|
|
Initial
dependence on unfamiliar partners;
|
||
|
||||
•
|
|
Insufficient
revenues to offset increased expenses associated with acquisitions;
and
|
||
|
||||
•
|
|
The
potential loss of key employees of the acquired companies.
|
•
|
|
Issue
common stock that would dilute our current shareholders’ percentage
ownership;
|
||
|
||||
•
|
|
Assume
liabilities;
|
||
|
||||
•
|
|
Record
goodwill and non-amortizable intangible assets that will be subject
to
impairment testing on a regular basis and potential periodic impairment
charges;
|
•
|
|
Incur
amortization expenses related to certain intangible
assets;
|
||
|
||||
•
|
|
Incur
large and immediate write-offs, and restructuring and other related
expenses; or
|
||
|
||||
•
|
|
Become
subject to litigation.
|
· |
seasonality
of sales of cough, cold and allergy products;
|
· |
demand
for and market acceptance of our
products;
|
· |
insufficient
demand in the marketplace causing our distributors to return
product;
|
· |
the
development of new competitive products by
others;
|
· |
changes
in treatment practices of physicians who currently prescribe our
products;
|
· |
the
timing, release and competitiveness of our
products;
|
· |
the
mix of products that we sell during any time
period;
|
· |
increased
price competition;
|
· |
increased
expenses, whether related to marketing, product development,
administration or otherwise; and
|
· |
adverse
changes in the level of economic activity in the United States and
other
major regions in which we do
business.
|
·
|
timing
of market introduction of competitive
drugs;
|
·
|
lower
demonstrated clinical safety and efficacy compared to other
drugs;
|
·
|
lack
of cost-effectiveness;
|
·
|
pricing
and reimbursement policies of government and third party payors
such as
insurance companies, health maintenance organizations and other
health
plan administrators;
|
·
|
lack
of convenience or ease of
administration;
|
·
|
prevalence
and severity of adverse side
effects;
|
·
|
other
potential advantages of alternative treatment methods;
and
|
·
|
ineffective
marketing and distribution
support.
|
·
|
announcements
or developments related to the products of the Company’s
competitors;
|
·
|
quarterly
variations in the Company’s operating
expenses;
|
·
|
issuances
or sales of capital stock by the Company;
and
|
·
|
sales
of the common stock by the Company’s founders or other selling
stockholders.
|
2.1
|
Modification
Agreement and Release by and among the Company, TG United Pharmaceuticals,
Inc. and David Ambrose
|
|
3.1
|
Certificate
of Designation of Series A Preferred Stock
|
|
3.2
|
Certificate
of Designation of Series B Preferred Stock
|
|
4.1
|
Registration
Rights Agreement by and between the Company and David
Ambrose
|
|
31.1
|
|
Certification
of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.
|
31.2
|
|
Certification
of the Chief Financial Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
|
32.1
|
|
Certification
of the Chief Executive Officer and Chief Financial Officer Pursuant
to 18
U.S.C. 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley
Act
of 2002.
|
99.1
|
Press
Release
|
|
Neuro-Hitech,
Inc.
|
|
|
(Registrant)
|
|
|
|
|
Date:
November 19, 2008
|
By:
|
/s/
Matthew E. Colpoys
|
|
Matthew
E. Colpoys
|
|
|
President
and Chief Executive Officer
|
|
|
|
|
Date:
November 19, 2008
|
By:
|
/s/
David J. Barrett
|
|
David
J. Barrett
|
|
|
Chief
Financial Officer
|